Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: Potential role of BRAFV600E mutation in defining CND

Endocrine-Related Cancer

Volumn 20, Issue 1, 2013, Pages 13-22

  Alzahrani, Ali S ^a   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF mutation; Lymph node metastasis; Neck dissection; Papillary thyroid cancer; Thyroid cancer recurrence

Indexed keywords

B RAF KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; DISEASE ACTIVITY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NECK DISSECTION; PAPILLARY THYROID CANCER; PREDICTIVE VALUE; RECURRENCE RISK; RISK ASSESSMENT; SCHOOL CHILD; THYROID CANCER; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NECK DISSECTION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; YOUNG ADULT;

EID: 84874068993     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0309     Document Type: Article

References (46)

1. Ahn JE, Lee JH, Yi JS, Shong YK, Hong SJ, Lee DH, Choi CG & Kim SJ 2008 Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World Journal of Surgery 32 1552-1558. (doi:10.1007/s00268-008-9588-7)
2. Arturi F, Russo D, Giuffrida D, Ippolito A, Perrotti N, Vigneri R & Filetti S 1997 Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. Journal of Clinical Endocrinology and Metabolism 82 1638-1641. (doi:10.1210/jc.82.5.1638)
3. CartySE,CooperDS,DohertyGM,DuhQY,KloosRT,MandelSJ,RandolphGW, Stack BC, Jr, Steward DL, Terris DJ et al. 2009 Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 19 1153-1158. (doi:10.1089/thy.2009.0159)
4. Chen AY, Jemal A & Ward EM 2009 Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115 3801-3807. (doi:10.1002/cncr.24416)
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19 1167-1214. (doi:10.1089/thy.2009.0110)
6. Davidson HC, Park BJ & Johnson JT 2008 Papillary thyroid cancer: controversies in the management of neck metastasis. Laryngoscope 118 2161-2165. (doi:10.1097/MLG.0b013e31818550f6)
7. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167. (doi:10.1001/jama.295.18.2164)
8. Elisei R, Ugolini C, ViolaD, LupiC, Biagini A, Giannini R, RomeiC,Miccoli P, Pinchera A & Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Journal of Clinical Endocrinology and Metabolism 93 3943-3949. (doi:10.1210/jc.2008-0607)
9. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L & Vitti P 2010 American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Journal of Endocrinological Investigation 33 51-56.
10. Gimm O, Rath FW & Dralle H 1998 Pattern of lymph node metastases in papillary thyroid carcinoma. British Journal of Surgery 85 252-254. (doi:10.1046/j.1365-2168.1998.00510.x)
11. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A & Vitale M 2012a A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology and Metabolism 97 2333-2340. (doi:10.1210/jc.2011-3106)
12. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G et al. 2012b The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 97 517-524. (doi:10.1210/jc.2011-0618)
13. Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, NikiforovaMN, Nikiforov YE et al. 2011 Both BRAF V600E mutation and older age (O/Z65 years) are associated with recurrent papillary thyroid cancer. Annals of Surgical Oncology 18 3566-3571. (doi:10.1245/s10434-011-1781- 5)
14. Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE & Yip L 2013 BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Annals of Surgical Oncology 20 47-52. (doi:10.1245/s10434-012- 2611-0)
15. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA. 2011 SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, USA. Available at http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
16. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S et al. 2006 Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer 119 2322-2329. (doi:10.1002/ijc.22110)
17. Hughes DT & Doherty GM 2011 Central neck dissection for papillary thyroid cancer. Cancer Control 18 83-88.
18. Joo JY, Park JY, Yoon YH, Choi B, Kim JM, Jo YS, Shong M & Koo BS 2012 Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. Journal of Clinical Endocrinology and Metabolism 97 3996-4003. (doi:10.1210/jc.2012-2444)
19. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B & Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery 246 466-470. (doi:10.1097/SLA. 0b013e318148563d)
20. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH et al. 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118 1764-1773. (doi:10.1002/cncr.26500)
21. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE & Evans DB 2003 Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134 946-954 (discussion 954-945). (doi:10.1016/S0039- 6060(03)00424-0)
22. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI & Evans DB 2004 Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136 1183-1191. (doi:10.1016/j.surg.2004.06.045)
23. Leenhardt L, Grosclaude P & Cherie-Challine L 2004 Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee Thyroid 14 1056-1060. (doi:10.1089/thy.2004.14.1056)
24. Li C, Lee KC, Schneider EB & Zeiger MA 2012 BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 97 4559-4570. (doi:10.1210/jc.2012-2104)
25. Machens A, Hinze R, Thomusch O & Dralle H 2002 Pattern of nodal metastasis for primary and reoperative thyroid cancer. World Journal of Surgery 26 22-28. (doi:10.1007/s00268-001-0176-3)
26. Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97 418-428. (doi:10.1016/0002-9343(94)90321-2)
27. Mazzaferri EL, Doherty GM & Steward DL 2009 The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 19 683-689. (doi:10.1089/thy.2009.1578)
28. Nikiforov YE & Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. Nature Reviews. Endocrinology 7 569-580. (doi:10.1038/ nrendo.2011.142)
29. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E et al. 2010 B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. PNAS 107 10649-10654. (doi:10.1073/pnas.1004934107)
30. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 154 787-803. (doi:10.1530/eje.1.02158)
31. Pereira JA, Jimeno J,Miquel J, IglesiasM, Munne A, Sancho JJ & Sitges-Serra A 2005 Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 138 1095-1100 (discussion 1100-1091). (doi:10.1016/j.surg.2005.09.013)
32. Roh JL, Park JY, Rha KS & Park CI 2007 Is central neck dissection necessary for the treatment of lateral cervical nodal recurrence of papillary thyroid carcinoma? Head & Neck 29 901-906. (doi:10.1002/hed.20606)
33. Roh JL, Kim JM & Park CI 2011 Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence. Annals of Surgical Oncology 18 2245-2250. (doi:10.1245/s10434-011-1600-z)
34. Rosenbaum MA & McHenry CR 2009 Central neck dissection for papillary thyroid cancer. Archives of Otolaryngology - Head & Neck Surgery 135 1092-1097. (doi:10.1001/archoto.2009.158)
35. Scheumann GF, Gimm O, Wegener G, Hundeshagen H & Dralle H 1994 Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World Journal of Surgery 18 559-567 (discussion 567-558). (doi:10.1007/BF00353765)
36. Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, Reading CC & Charboneau JW 2006 Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Archives of Surgery 141 489-494 (discussion 494-486). (doi:10.1001/archsurg.141. 5.489)
37. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S & Delbridge L 2006 Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 140 1000-1005 (discussion 1005-1007). (doi:10.1016/j.surg.2006.08.001)
38. Tisell LE, Nilsson B, Molne J, Hansson G, FjallingM, Jansson S &Wingren U 1996 Improved survival of patients with papillary thyroid cancer after surgical microdissection. World Journal of Surgery 20 854-859. (doi:10.1007/s002689900130)
39. Tufano RP, Teixeira GV, Bishop J, Carson KA & Xing M 2012 BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 91 274-286. (doi:10.1097/MD.0b013e31826a9c71)
40. Vergez S, Sarini J, Percodani J, Serrano E & Caron P 2010 Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. European Journal of Surgical Oncology 36 777-782. (doi:10.1016/j.ejso.2010.06.015)
41. Xing M 2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262. (doi:10.1677/erc.1.0978)
42. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762. (doi:10.1210/er.2007-0007)
43. Xing M 2009 Prognostic utility of BRAF mutation in papillary thyroid cancer. Molecular and Cellular Endocrinology 321 86-93. (doi:10.1016/j. mce.2009.10.012)
44. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6379. (doi:10.1210/jc.2005-0987)
45. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M et al. 2009 BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. Journal of Clinical Oncology 27 2977-2982. (doi:10.1200/JCO. 2008.20.1426)
46. Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB & Nikiforov YE 2009 Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146 1215-1223. (doi:10.1016/j.surg. 2009.09.011)